4D Molecular Therapeutics (FDMT) Current Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Current Leases data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Current Leases fell 3.4% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a 3.4% decrease from a year earlier, with the FY2025 full-year figure at $5.6 million, down 0.8% from the prior year.
• Current Leases for Q1 2026 stood at $5.5 million, down from $5.6 million in the prior quarter.
• Over the last five years, Current Leases for FDMT reached as high as $5.7 million in Q2 2025 and fell as low as $2.0 million in Q1 2022.
• Historically, Current Leases has averaged $4.0 million across 5 years, with a median of $3.2 million in 2024.
• Across the five-year window, Current Leases surged 115.68% in 2022 and retreated 3.4% in 2026, its largest moves.
• Year by year, Current Leases stood at $2.7 million in 2022, then rose by 18.61% to $3.1 million in 2023, then jumped by 79.01% to $5.6 million in 2024, then declined by 0.8% to $5.6 million in 2025, then declined by 1.9% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $5.5 million in Q1 2026, $5.6 million in Q4 2025, and $5.7 million in Q3 2025.